Logo

Vertex's VX-880 Receives the US FDA's Fast Track Designation for T1D

Share this

Vertex's VX-880 Receives the US FDA's Fast Track Designation for T1D

Shots:

  • The US FDA has granted FTD for VX-880 to treat T1D. The designation is designed to facilitate the development and expedite the review of treatments for serious condition and fill an unmet medical need
  • Additionally- the company has initiated P-I/II trial for VX-880 in ~17 patients who have T1D with severe hypoglycemia and impaired hypoglycemic awareness
  • VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated- insulin-producing pancreatic islet cells for the treatment of T1D

 ­ Ref: Businesswire | Image: Vertex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions